Fenclofenac was studied in two groups of patients suffering from osteoarthrosis.
First Study -Double-blind Comparison of Fenclofenac versus Placebo
In the first study, 17 patients suffering from osteoarthrosis of the hip were randomly allocated to either fenclofenac (900 mg/day) for 21 days followed by a matching placebo for an identical period or the same agents were administered in the reverse order. Paracetamol up to 4 g daily was permitted as an optional additional analgesic.
Results
Significant results favouring fenclofenac were achieved in respect of overall pain level, night pain level, morning stiffness, paracetamol consumption and patient preference (P<0.05). Twelve patients preferred fenclofenac, 3 placebo, whilst 2 patients expressed no preference. There was no significant difference in the range of hip abduction or hip rotation between fenclofenac and placebo (Table 1 ). There were no significant changes in hemoglobin, white cell and platelet count, serum bilirubin, aspartate aminotransferase, urea, creatinine and plasma proteins. Urinalysis was normal throughout (Table 2) .
Side-effects Whilst on fenclofenac 3 patients reported mild indigestion and one constipation. Whilst on placebo, 2 patients reported mild diarrhoea, one constipation and one ankle swelling.
Second Study -Double-blind Comparison of Fenclofenac versus Ibuprofen In the second study, fenclofenac in a higher dose of 1200 mg daily was compared in a double-blind cross-over study with ibuprofen 1200 mg daily. As unmarked ibuprofen tablets and matching placebos were not made available to us, both fenclofenac and ibuprofen tablets were enclosed in dry-seal charcoal-grey cachets, thereby maintaining double-blind conditions in the trial. Twentytwo patients suffering from osteoarthrosis of various sites were admitted to the study and allocated to either fenclofenac (1200 mg) or ibuprofen (1200 mg) in a random manner for a 14-day period. At the end of this time, the patients were crossed to the alternative therapy for a further 14-day period. A three-day washout period preceded the first treatment period and during this time paracetamol 4 g daily was permitted. Paracetamol was also allowed during the course of the trial as an additional optional analgesic.
Clinical and laboratory assessments were carried out on Days 0, 14 and 28. The following parameters were measured: degree of overall pain and night pain, duration of pain relief, range of joint movement, early morning stiffness, paracetamol tablet count and unwanted effects. Patients were also asked to express preference for either of the two-week periods of therapy. Hematological and biochemical screening was carried out on Days -3, 14 and 28. The tests carried out were as listed in the first study. 
There were no significant differences encountered between the two treatments in respect of any of the parameters (Tables 3 and 4 ). Nine patients preferred fenclofenac, 9 ibuprofen, whilst the remaining patient expressed no preference.
Tolerance and Side-effects Fifteen patients reported that both treatments suited them. Two reported that fenclofenac suited them but ibuprofen did not, whilst 2 reported that ibuprofen suited them but fenclofenac did not.
Side-effects were encountered by 7 patients whilst on fenclofenac and by 6 patients on ibuprofen ( Table 5 ). Most of these were mild. Three patients were withdrawn because of a maculopapular rash 2 on fenclofenac and one on ibuprofen. In one patient on fenclofenac, the rash which occurred 12 days after starting the drug was accompanied by a transient leukopenia. The white cell count fell from 5200/mm3 to 2600/mm3 (polymorphonuclear leukocytes 1400, lymphocytes 754, eosinophils 156). Fourteen days after stopping the drug, the rash faded and the white cell count rose to 6200/mm3. 
Discussion
Our studies show that fenclofenac is effective in relieving the symptoms of osteoarthrosis. It is shown to be superior to a placebo and of comparable efficacy to ibuprofen. At a dose of 900 mg daily side-effects were insignificant, but at a higher dose of 1200 mg per day 2 patients out of 22 developed a rash. Both the fenclofenac patient who developed the rash with leukopenia and the ibuprofen patient who developed a rash gave a history of penicillin sensitivity. It would seem wise to use non-steroidal anti-inflammatory drugs with caution in patients known to have experienced previous drug allergies.
